Australia's most trusted
source of pharma news
Posted 23 June 2022 PM
BMS, Pfizer, and MSD are heading towards a huge patent cliff before the end of the decade with brutal financial consequences.
But according to ratings agency Moody's they each have the funds to open a parachute of mergers and acquisitions to soften the fall.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.